FIZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FIZZ is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act immediately. The stock is trading near short-term resistance, momentum is overextended, analyst sentiment is still bearish, and there is no fresh news or strong proprietary buy signal to support an entry. Based on the current data, I would not buy it now.
Short-term momentum is positive but stretched. MACD histogram is above zero and expanding, which supports the current upward move, but RSI_6 at 82.49 is strongly overbought. The price at 37.23 is sitting just below R2 at 37.656 and above R1 at 36.913, suggesting limited upside near term and higher odds of a pullback. Moving averages are converging, which signals the trend is not yet firmly established for a clean long-term entry. The next-day pattern data also points to a probable slight decline.
No news in the recent week means there are no fresh event-driven positives or company-specific catalysts to support immediate buying. The only mild positive is that MACD momentum is improving and the stock is holding above the pivot level of 35.709.
RSI is deeply overbought, the stock is near resistance, and similar candlestick pattern data suggests a 70% chance of a -0.95% move next day. Analysts remain bearish with UBS maintaining a Sell rating and a target below the current price. There is no recent news, no strong insider buying, no hedge fund accumulation trend, and no recent congress trading activity.
No usable latest-quarter financial snapshot was provided due to a data error, so I cannot confirm the most recent quarter season or growth trends from the supplied data.
Recent analyst trend is weak. UBS raised its price target to $35 from $34 on 2026-03-16 but kept a Sell rating, and previously lowered the target from $35 to $34 on 2026-03-10 while also maintaining Sell. That shows only minor target movement, but the Wall Street view remains negative overall: the bearish case is that the stock appears priced above UBS's target, while the bullish case is limited to the fact that the target was nudged slightly higher. Net view from pros is still clearly negative.
